Sign in
CRVS Stock Price, Chart, Stats & News
Corvus Pharmaceuticals, Inc.
Save
1.06B
Market cap
–
Current P/E
–
Forward P/E
CRVS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.49% |
ROE | -23.29% |
D/E | 0.02x |
Interest coverage ratio | – |
CRVS valuation
P/E | – |
P/S | – |
P/B | 18.08x |
P/CF | -33.73x |
P/FCF | -35.69x |
P/OCF | -33.73x |
PEG | -0.72x |
EV multiple | -27.81x |
About
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor.
Similar securities
Based on sector and market capitalization
Report issue